title: Vaccination of cattle with Mycobacterium bovis BCG by a combination of systemic and oral routes.
abstract: Mycobacterium bovis bacille Calmette-Guérin (BCG) vaccine delivered to calves by the subcutaneous (s.c.) or by the oral route in a formulated lipid matrix has been previously shown to induce similar levels of protection against bovine tuberculosis. The current study was aimed at determining whether a combination of delivering BCG by s.c. and oral routes would enhance levels of protection, compared to only one route of vaccination. Forty calves were randomly divided into four groups (10/group). Calves were vaccinated with 10(6)colony forming units (CFU) of BCG Pasteur by the s.c. route or orally with 10(9)CFU BCG incorporated into a lipid formulation. One group received a combination of BCG administered by both the s.c. and oral routes and a non-vaccinated group served as a control. The two groups of calves that received s.c. BCG produced strong IFN-gamma responses in whole blood cultures stimulated with bovine purified protein derivative (PPD) 3 weeks after vaccination. Cattle vaccinated just with oral BCG in a lipid matrix produced a strong IFN-gamma response 8 weeks after vaccination, and peaking at 11 weeks after vaccination. All calves were challenged by the intratracheal route with M. bovis 15 weeks after vaccination and were euthanized and necropsied to assess protection at 17 weeks following challenge. BCG given s.c. or orally induced significant and comparable levels of protection against the virulent challenge. Vaccination of cattle by a combination of s.c./oral routes did not enhance protection beyond that achieved by s.c. or oral vaccination alone. We conclude that vaccination of cattle with BCG by a combination of routes has no beneficial additive effects, compared to a single s.c. administration of BCG or BCG given orally in a lipid formulation.
authors.affiliation: AgResearch, Hopkirk Research Institute, Grasslands Research Centre, Tennent Drive, Private Bag 11008, Palmerston North, New Zealand. bryce.buddle@agresearch.co.nz
authors.forename: Bryce M
authors.initials: BM
authors.lastname: Buddle
authors.forename: Michel
authors.initials: M
authors.lastname: Denis
authors.forename: Frank E
authors.initials: FE
authors.lastname: Aldwell
authors.forename: H
authors.initials: H
authors.lastname: Martin Vordermeier
authors.forename: R
authors.initials: R
authors.lastname: Glyn Hewinson
authors.forename: D
authors.initials: D
authors.lastname: Neil Wedlock
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000284:Administration, Oral; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D001500:BCG Vaccine / Q000008:administration & dosage*; D002417:Cattle; D015169:Colony Count, Microbial / Q000662:veterinary; D005260:Female; D007279:Injections, Subcutaneous; D007371:Interferon-gamma / Q000097:blood; D008168:Lung / Q000473:pathology; D009163:Mycobacterium bovis; D014374:Tuberculin Test / Q000662:veterinary; D014380:Tuberculosis, Bovine / Q000276:immunology* / Q000473:pathology / Q000517:prevention & control
chemical_list: D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D001500:BCG Vaccine; D007371:Interferon-gamma